Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Dise...
May 15 2013 - 1:00AM
May 15, 2013
TORONTO - Cynapsus Therapeutics Inc. (CTH: TSX-V),
a specialty pharmaceutical company developing the only known orally
administered (sublingual) formulation of apomorphine, the only drug
approved to treat the immobility ("off") symptoms of Parkinson's
disease, has completed a white paper providing background clinical
information on apomorphine. The paper identifies the potential
benefits of APL-130277, the company's proprietary, patented,
sublingual thin-film strip system, specifically its ability to
deliver apomorphine to patients in a more convenient and more
well-tolerated manner.
Anthony Giovinazzo, President and Chief Executive
Officer of Cynapsus, stated: "We have been receiving requests for a
more comprehensive, clinically based summary of apomorphine,
covering its benefits, drawbacks and known side effects, as well as
a summary of our development delivery candidate APL-130277-all in a
single document. Accordingly, we have composed this background
paper, which is now available on our website. It offers useful
information to anyone who is interested in these topics."
The white paper is titled "Apomorphine for Off
Periods in Parkinson's Disease: Clinical Use and Potential of a
Developmental Sublingual Formulation, APL-130277". It summarizes
the medical literature on the freezing or "off" episodes
experienced by 25 percent to 50 percent of Parkinson's patients. It
goes on to identify how apomorphine works as an acute intermittent
rescue treatment. Further, it summarizes some of the most pertinent
data from a recent survey of 500 neurologists worldwide regarding
the number of patients who will potentially experience these "off"
episodes. It then identifies past efforts to find new delivery
methods and the benefits of the new APL-130277 sublingual approach.
The paper reviews clinical data generated to date and further data
expected through the remainder of 2013. It also includes
predictions by the 500 neurologists regarding the potential use of
the new delivery method by Parkinson's patients who experience the
"off" episodes.
A copy of the full paper is available at the
Cynapsus website, www.cynapsus.ca
The TSX Venture Exchange has not reviewed and does
not accept responsibility for the adequacy or accuracy of this
press release.
About Cynapsus Therapeutics
Cynapsus is a specialty pharmaceutical company
developing the only known orally administered (i.e. sublingual)
delivery of the only approved drug (apomorphine) to be used as a
rescue therapy for "off" motor symptoms of Parkinson's disease.
Apomorphine is currently primarily delivered as an inconvenient and
painful subcutaneous injection. Over one million people in the U.S.
and an estimated 5 million people globally suffer from Parkinson's
disease. Parkinson's disease is a chronic and progressive
neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging of the population. Based on
a recent study and the results of the Company's Global 500
Neurologists Survey, it is estimated that between 25 percent and 50
percent of patients experience "off" episodes in which they have
impaired movement or speaking capabilities. Current medications
only control the disease's symptoms, and most drugs become less
effective over time as the disease progresses. Cynapsus' drug
candidate, APL-130277, is an easy-to-administer, fast-acting
reformulation of apomorphine, which is approved in an injection
formulation to rescue patients from "off" episodes.
Cynapsus is focused on maximizing the value of
APL-130277 by completing pivotal studies in advance of a New Drug
Application expected to be submitted in 2015. Cynapsus anticipates
a trade sale or out-licensing to an appropriate global
pharmaceutical partner before such an application is
submitted.
More information about Cynapsus (CTH: TSX-V) is
available at www.cynapsus.ca and at the System for Electronic
Document Analysis and Retrieval (SEDAR) at
www.sedar.com.
Contact
Information
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
ajg@cynapsus.ca
Andrew Williams
COO & CFO
(416) 703-2449 x253
awilliams@cynapsus.ca
Forward Looking
Statements
This announcement contains "forward-looking
statements" within the meaning of applicable Canadian securities
legislation. Generally, these forward-looking statements can be
identified by the use of forward-looking terminology such as
"plans", "expects" or "does not expect", "is expected", "budget",
"scheduled", "estimates", "forecasts", "intends", "anticipates" or
"does not anticipate", or "believes" or variations of such words
and phrases or state that certain actions, events or results "may",
"could", "would", "might" or "will be taken", "occur" or "be
achieved". Forward-looking statements are subject to known and
unknown risks, uncertainties and other factors that may cause the
actual results, level of activity, performance or achievements of
Cynapsus to be materially different from those expressed or implied
by such forward-looking statements, including but not limited to
those risks and uncertainties relating to Cynapsus' business
disclosed under the heading "Risk Factors" in its Annual
Information Form filed on November 1, 2012 and its other filings
with the various Canadian securities regulators which are available
online at www.sedar.com. Although Cynapsus has attempted to
identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements, there may be other factors that cause results not to be
as anticipated, estimated or intended. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on forward-looking statements. Cynapsus does not undertake
to update any forward-looking statements, except in accordance with
applicable securities laws.
-30-
This
announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the
information contained therein.
Source: Cynapsus Therapeutics Inc. via Thomson Reuters
ONE
HUG#1701878
Citigroup Fdg (AMEX:CTH)
Historical Stock Chart
From Apr 2024 to May 2024
Citigroup Fdg (AMEX:CTH)
Historical Stock Chart
From May 2023 to May 2024